Current Approaches to HCV Infection in Current and Former Injection Drug Users
Authors:
- Fiona DuncanFDFiona Duncan
- Mark ViljoenMVMark Viljoen
- Brian ConwayBCBrian Conway
- Ph DPDPh D
- MdMDMd
- 27 February 2008
- journal article
- review article
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 27 (2) , 25-35
Abstract
Injection drug use (IDU) accounts for 75% of incident cases of hepatitis C virus (HCV) infection in the developed world. Of those infected with HCV, up to 80% will go on to develop chronic disease. Intervention with effective treatment in eligible subjects will limit the impact of the long-term consequences of infection. The use of combination therapy with pegylated interferon and ribavirin may lead to a cure in up to 80% of treated individuals who carry genotype 2 or 3 isolates. Such individuals account for up to 45% of certain cohorts, such as in the inner city of Vancouver. Historically, many IDUs have not received treatment for HCV infection even if it were medically indicated. Recent data (including our own) suggest that, in the right context, response rates similar to those reported in clinical trials of HCV therapy can be achieved in IDUs, even with ongoing drug use. This is all the more important given that prior infection may protect against re-infection even in the presence of ongoing risk behaviors for HCV transmission. The keys to a successful program appear to be appropriate patient selection as well as the delivery of care within an appropriate setting, preferably with a multidisciplinary team in a way that addresses the issue of addiction and other conditions simultaneously. The development of such programs may be quite complex, but the ultimate benefit (for the treated population and for society as a whole) is certainly worth the effort.Keywords
This publication has 70 references indexed in Scilit:
- Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facilityPublic Health, 2005
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Natural History of Hepatitis CClinics in Liver Disease, 2005
- Guidelines for the Treatment of Hepatitis C Virus Infection in Injection Drug Users: Status Quo in the European Union CountriesClinical Infectious Diseases, 2005
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Appendix: The National Institutes of Health Consensus Development ConferenceClinics in Liver Disease, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Epidemiology of hepatitis CHepatology, 1997
- Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.American Journal of Public Health, 1996
- Correlates of Hepatitis C Virus Infections among Injection Drug UsersMedicine, 1995